‍

High Purity UDCA Ingredients for Liver Function Improvement and Detoxification

Daewoong Pet (Co-CEOs Lee Hyo-jun and Moon Jae-bong), a company specializing in pet healthcare, announced on the 27th that it has launched the first domestic UDCA-based tablet for pets, UDCA Tablets, to improve liver health in pets and provide a new treatment option for liver and bile duct diseases in pets.

Developed using the long-established technology behind Ursapet, Daewoong Pharmaceutical’s liver function improvement drug, UDCA Tablets for pets are a new liver function improvement drug for pets, with UDCA (Ursodeoxycholic Acid) as the main ingredient. This product is sold exclusively in veterinary hospitals, with each tablet containing 200 mg of UDCA.

Previously, UDCA-based drugs developed for humans were divided and adjusted for use in pets. However, using human drugs for pets had the issue of low palatability when taken alone.

To address this, Daewoong Pet has launched UDCA Tablets, the only UDCA tablet specifically for pets, presenting a new treatment option for liver and bile duct diseases. The tablets are designed in a soft, chewable form, making them easier and more palatable for pets to consume. UDCA Tablets are to be administered orally at a dose of 10-15 mg per kg of body weight, once or twice a day.

The UDCA in the product promotes bile secretion, helping to expel accumulated waste in the liver and activating detoxification. Additionally, its antioxidant properties help protect liver cells by removing reactive oxygen species.

Pets are prone to liver and bile duct diseases due to aging, weakened liver and gallbladder function, or bacterial infections. Since pet food is not as meticulously managed as human food, pets are often exposed to disease-causing germs. With UDCA Tablets, Daewoong Pet aims to protect the liver cells of pets suffering from liver and bile duct diseases and improve their liver function.

UDCA Tablets were approved by the Animal and Plant Quarantine Agency in February for improving liver function and treating conditions such as acute and chronic hepatitis, liver enlargement, fatty liver, jaundice prevention and treatment, and bile secretion deficiency. With this launch, Daewoong Pet is expanding its position in the pet market, offering not only health supplements but also animal pharmaceuticals from its core brand.

Moreover, UDCA Tablets are made using high-purity, high-quality raw materials supplied by Daewoong Bio, which supplies over 25% of the world's UDCA raw materials, ensuring the product's reliability.

Daewoong Pet also launched Epicle (EPICLE), the world’s first rapid-release pancreatic enzyme supplement, in July last year, and within 9 months, it sold approximately 15,000 units, securing 42% of the domestic market for pancreatic enzyme supplements in veterinary hospitals. With the launch of UDCA Tablets, the company plans to expand its market share in the treatment of liver and bile duct diseases, in addition to the pancreatic enzyme supplement market.

Lee Hyo-jun, CEO of Daewoong Pet, stated, “UDCA Tablets is a product that has garnered great expectations and interest from the industry even before its launch, as it uses Daewoong Pharmaceutical’s core brand’s ingredients in a version for animals. For this, we consulted with over 200 industry experts and clinical veterinarians to reflect their opinions. We developed it as a chewable tablet with increased palatability, enabling it to be prescribed alone or customized according to the needs of each hospital. In the future, we will continue to launch animal medicines with proven efficacy and safety, creating an environment where pets can receive safe treatments."

Meanwhile, UDCA Tablets were officially launched on the 27th and can be purchased from specialized online veterinary pharmacies such as theSHOP, Seoul Veterinary Pharmaceuticals, Veterinary Marketplace, and BlueVet.